跳至主要内容
临床试验/NCT07730606
NCT07730606招募中3 期

Evaluation of the Effect of Acute Sodium Bicarbonate Supplementation on Physical Capacity and Blood Biochemical Marker Concentrations in Highly Trained Female Basketball Players

Krzysztof Durkalec-Michalski1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年3月1日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Changes in anaerobic power during the repeated modified Wingate Anaerobic Test

研究概览

简要总结

This randomized, double-blind, placebo-controlled crossover study aims to evaluate the effect of acute sodium bicarbonate supplementation, compared with placebo, on physical capacity and blood biochemical marker concentrations in highly trained female basketball players.

详细描述

Sodium bicarbonate (SB) is commonly proposed as an ergogenic aid due to its potential to enhance extracellular buffering capacity, thereby supporting acid-base balance and delaying fatigue during repeated high-intensity exercise. This mechanism may be particularly relevant in basketball, where performance depends on repeated short-duration, high-intensity efforts, rapid recovery between actions, and the ability to maintain power output during demanding phases of play. Although the ergogenic effects of SB supplementation have been widely investigated, existing evidence has primarily focused on male participants, and data regarding highly trained female athletes remain limited. This creates an important knowledge gap, especially in team sports such as basketball, where sex-specific physiological responses, training status, and sport-specific demands may influence the effectiveness and tolerability of supplementation strategies. This study will evaluate the effect of a single dose of SB compared with placebo. Participants will receive SB or placebo in a randomized, double-blind, placebo-controlled crossover design. The SB dose will be 0.3 g/kg body mass, administered 90 minutes before the exercise protocol, with intervention visits separated by a washout period. By using a randomized, double-blind, placebo-controlled crossover design, this study will allow for the evaluation of individual responses to acute SB supplementation under controlled laboratory conditions. The findings may help clarify whether acute SB intake is an effective and tolerable strategy for supporting physical capacity and biochemical responses in highly trained female basketball players.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
16 Years 至 35 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • female sex,
  • age 16 to 35 years,
  • good general health condition and well-being,
  • regular menstrual cycles,
  • written informed consent to participate in the study before its commencement,
  • at least a high level of training status,
  • at least 4 years of training experience in basketball,
  • participation in at least 3 basketball-specific training sessions per week,
  • participation in at least 1 basketball game per week.

排除标准

  • male sex,
  • use of hormonal contraceptives,
  • current injury or musculoskeletal condition limiting participation in training or competition,
  • health-related or medical contraindications, including menstrual disorders, planned pregnancy, or anemia,
  • use of supplements within 3 months before the study, except for regular use of protein supplements, carbohydrate supplements, or isotonic drinks,
  • failure to meet the study protocol assumptions or unwillingness to follow study procedures.

结局指标

主要结局

Changes in anaerobic power during the repeated modified Wingate Anaerobic Test

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of peak power (PP), average power (AP), minimum power (MP), and power drop (PD) \[W (watts)\] during the repeated modified Wingate Anaerobic Test using the Monark 894E cycle ergometer (Monark, Sweden)

Changes in interval mean power during the repeated modified Wingate Anaerobic Test

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of mean power \[W (watts)\] in predefined 5 second intervals, including 1 to 5 s and 6 to 10 s, during each 10 second effort of the repeated modified Wingate Anaerobic Test using the Monark 894E cycle ergometer (Monark, Sweden)

Changes in second-by-second power output during the repeated modified Wingate Anaerobic Test

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of power output \[W (watts)\] for each 1 second segment, including 1 s, 2 s, 3 s, 4 s, 5 s, 6 s, 7 s, 8 s, 9 s, and 10 s, during each 10 second effort of the repeated modified Wingate Anaerobic Test using the Monark 894E cycle ergometer (Monark, Sweden)

Changes in time to peak power during the repeated modified Wingate Anaerobic Test

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of time to peak power (TTP) \[s (seconds)\] during each 10 second effort of the repeated modified Wingate Anaerobic Test using the Monark 894E cycle ergometer (Monark, Sweden)

Changes in countermovement jump height

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of countermovement jump (CMJ) height \[cm (centimeters)\] during three consecutive CMJ attempts using the OptoJump Next optical measurement system (Microgate, Italy)

Changes in countermovement jump power

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of countermovement jump (CMJ) power \[W (watts)\] during three consecutive CMJ attempts using the OptoJump Next optical measurement system (Microgate, Italy).

Changes in blood bicarbonate, base excess, anion gap, and lactate concentrations

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of blood bicarbonate, base excess, anion gap, and lactate concentrations \[mmol/L\] in capillary blood using the ABL90 FLEX PLUS blood gas analyzer (Radiometer, Denmark)

Changes in hydrogen ion concentration

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of hydrogen ion concentration \[nmol/L\] in capillary blood using the ABL90 FLEX PLUS blood gas analyzer (Radiometer, Denmark)

Changes in pH in blood

时间窗: At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2)

Assessment of blood pH \[pH units\] in capillary blood using the ABL90 FLEX PLUS blood gas analyzer (Radiometer, Denmark)

次要结局

  • Changes in oxygen uptake, carbon dioxide production, and minute ventilation during the repeated modified Wingate Anaerobic Test(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in relative oxygen uptake during the repeated modified Wingate Anaerobic Test(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in respiratory exchange ratio during the repeated modified Wingate Anaerobic Test(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in breathing frequency during the repeated modified Wingate Anaerobic Test(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in tidal volume during the repeated modified Wingate Anaerobic Test(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in heart rate during the exercise protocol(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in rate of perceived exertion(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in gastrointestinal symptoms(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in body mass, fat-free mass, fat mass, total body water, intracellular water, and extracellular water(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in fat-free mass percentage, fat mass percentage, total body water percentage, intracellular water percentage, and extracellular water percentage(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in white blood cell count, white blood cell subpopulations, red blood cell count, and platelet count(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in hemoglobin concentration(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in hematocrit(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in alanine aminotransferase, aspartate aminotransferase, creatine kinase, and lactate dehydrogenase activities(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in creatinine concentration(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in urea concentration(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in iron, unsaturated iron-binding capacity, and total iron-binding capacity concentrations(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in ferritin concentration(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in transferrin concentration(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in partial pressure of carbon dioxide and oxygen(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in oxygen saturation and hemoglobin fractions(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in potassium, sodium, ionized calcium, and chloride concentration(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in plasma osmolality(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in dietary energy intake(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))
  • Changes in dietary macronutrient intake(At the Day 0 (familiarization visit), Day 7 (baseline visit), Day 14 (experimental visit 1), and Day 21 (experimental visit 2))

研究者

发起方
Krzysztof Durkalec-Michalski
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Krzysztof Durkalec-Michalski

Prof.

Poznan University of Physical Education

研究点 (1)

Loading locations...

相似试验